Core Insights - Ocean Biomedical has developed a unique oncology platform targeting CHI3L1 to activate natural immune responses against various cancers, including lung cancer, glioblastoma, prostate cancer, melanoma, and breast cancer [1][2][4] Research and Development - New research published in the Journal of Immunology reveals how CHI3L1 inhibits the body's immune responses, particularly macrophage phagocytosis, by activating two key checkpoint pathways [1] - The research indicates that inhibiting CHI3L1 can enhance adaptive immune responses and reduce cancer growth in both standard and humanized mouse models [1][4] Patent and Therapeutic Potential - Ocean Biomedical has received patent allowances for multiple cancers, including prostate, colon, rectal, ovarian, kidney, breast, glioblastoma, melanoma, and lung cancer [2] - The company aims to advance towards IND-enabling studies to develop new cancer therapeutics based on the mechanisms discovered [4] Leadership and Vision - Dr. Jack A. Elias, a leading specialist in pulmonary care and co-founder of Ocean Biomedical, emphasizes the significance of controlling CHI3L1 to manage multiple anti-cancer pathways [3] - The company is focused on addressing unmet medical needs by accelerating the transition of scientific discoveries into therapeutics [6]

Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE, Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of ...

Despite a preventative vaccine, cases of chronic hepatitis B (HBV) continue to rise, with an estimated 296 million persons infected worldwide and 820,000 deaths per year from HBV-related liver complications. This includes almost 100 million persons in China who are affected by this disease. Chronic HBV remains a global health issue with a high unmet medical need since there is no cure available. The current standard of care requires lifelong antiviral therapy to maintain control of the virus. Providence, RI ...

Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (V ...

Providence, RI, May 16, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted to both prevent malaria infection and treat severe malaria. Kurtis' novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This expands patent protection for Dr. Kurtis' novel discoveries at a ti ...

Core Insights - Ocean Biomedical has received a new patent for malaria therapeutic antibody discoveries aimed at preventing malaria infection and treating severe malaria, which is crucial given the rising resistance of malaria strains to current treatments [1][4][8] - The company's innovative approach targets the blood-stage of the malaria lifecycle, which is responsible for clinical disease and death, potentially offering greater efficacy compared to existing vaccines and therapeutics [3][4] - The patent enhances Ocean Biomedical's global patent portfolio, which focuses on addressing significant unmet medical needs in infectious diseases, oncology, and fibrosis [2] Company Developments - Dr. Jonathan Kurtis, the scientific co-founder, is leading research efforts in malaria treatment, with a focus on a "kill switch" mechanism that interrupts the malaria parasite's lifecycle [5][8] - Ocean Biomedical is in the process of optimizing its vaccine and therapeutic antibody formulation before submitting for Investigational New Drug (IND) approval and initiating first-in-human testing [3][6] - The company aims to develop five promising discoveries that could lead to life-changing outcomes in various diseases, including malaria, lung cancer, and pulmonary fibrosis [9] Industry Context - Malaria remains a significant global health threat, being the leading cause of death among children, with approximately 627,000 fatalities reported in 2022 [4] - The emergence of drug-resistant malaria strains poses a serious challenge to existing treatment methods, highlighting the urgent need for new anti-malarial drugs [4][8] - Ocean Biomedical's advancements in malaria treatment are positioned to address this critical public health issue and could potentially save tens of thousands of lives [6][8]

Management has evaluated subsequent events to determine if events or transactions occurring through the filing date of this Quarterly Report on Form 10-Q require adjustments to or disclosures in the Company's condensed consolidated financial statements. Aside from the items discussed below, the Company did not have any subsequent events that required recognition or disclosure in the condensed consolidated financial statements for the nine months ended September 30, 2023. On October 2, 2023, Poseidon loaned ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Commission File Number: 001-40793 OCEAN BIOMEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 87-1309280 55 Claverick St., Room 3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-40793 Ocean Biomedical, Inc. (Exact name of registrant as specified in its charter) Delaware 87-1309280 (I.R.S. Employer Identification No.) 55 Claverick St., Room 325 For the quarterly period ended March 31, 2023 Providence, RI 02903 or ☐ TRANSITION REPOR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-40793 Ocean Biomedical, Inc. (Exact name of registrant as specified in its charter) | Delaware | 87-1309280 | | --- | --- | ...